Apnimed's experimental drug reduced breathing interruptions by nearly 46.8% in clinical trials, offering a potential ...

Vizient® released its Summer 2025 Spend Management Outlook forecasting a 3.35% increase in pharmaceutical prices in 2026 with healthcare providers seeing increased usage in GLP-1 therapies, specialty ...